Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • The study has several strengths as well

    2019-08-16

    The study has several strengths as well. First, SEER and TCR data are highly valuable sources of patient information, tumor variables and survivorship. Both SEER and TCR met the national Centers for Disease Control (CDC) "high quality" data standards and received Gold certification (highest level) from North American Association of Central Cancer Registries (NAACCR). The completeness of case ascertainment in SEER program is as high as 98% [32] and is over 95% for TCR. The two datasets have a broad coverage of the U.S. population. Second, both datasets have a long follow-up time period, with SEER data available from 1975 to 2013 and TCR from 1995 to 2013, which allowed us to generate time trend analysis and long term survival analysis. Third, the study revealed the survival outcome for MCL patients in Texas for the first time, and the results suggest that TCR mirrors SEER. Lastly, this study updated the survival outcome for MCL patients to the most recent available years.
    Conclusion
    Author contributions
    Funding source This research was supported in part by the Cancer Prevention Research Institute of Texas (grant #: RP130051) and by the National Institute On Aging of the National Institutes of Health (grant #: R01AG058971). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.
    Conflicts of interest
    Acknowledgments
    Introduction The increasing incidence of cancer has placed a heavy burden on the management of this disease. Globally, the number of new cases of cancer increased to 14.1 million in 2012 [1]. Along with the increase in the number of incidences, the ABT-888 (Veliparib) of cancer survivors also increases. As of 2014, there were 14.5 million cancer survivors, a number that is expected to increase to 19 million by 2024 [2]. Cancer survivors are prone to increased incidence of comorbidities compared with the general population without a history of cancer [3]. Furthermore, the late effects of cancer treatment may lead to adverse outcomes. Among these outcomes, cardiovascular disease has been reported as one of the most prevalent comorbidities [3], contributing to the largest number of deaths among cancer survivors [4]. Thus, management of cardiovascular disease in cancer survivors has become an important issue. As one of the important predictive factors of cardiovascular disease, metabolic syndrome (MeS) has received increasing attention not only in the general population but also in cancer survivors [5]. MeS is considered a multiplex cardiovascular risk factor [6] and abnormalities in the clinical markers of MeS may promote the development of cardiovascular events [6]. Therefore, MeS in cancer survivors is an increasingly important issue for its potential cardiovascular disease-related burden, which remains the most common comorbidity in this population. Previous studies have investigated the prevalence of MeS in cancer survivors, but the results were inconsistent and based on limited sample sizes [5,7,8]. Additionally, vulnerability to MeS may differ according to cancer type [5,[9], [10], [11], [12]]. As the number of cancer survivors and their remaining years of life have increased, rehabilitation and health management among those who complete treatment and return to their normal lives have been emerging issues [13]. Management of cancer survivors should include strategies to control short- and long-term treatment complications as well as changes in health conditions after diagnosis or treatment [14,15]. However, most previous studies have considered MeS as a short-term side effect during cancer treatment [16,17]; thus, MeS among cancer survivors living in the general community has been ignored. As advances in cancer care have been achieved and survival rate after cancer has increased rapidly, cancer is considered a controllable and manageable disease that requires long-term care. In addition, physicians need to consider patients under treatment for cancer as individuals with chronic conditions [[18], [19], [20]]; therefore, the major long-term sequelae in cancer survivors require further investigation, particularly in comparison with patients with or without other chronic diseases. Studies on these topics are limited; thus, these data will help assess whether cancer should be considered a chronic disease.